Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5223 - One tumour, Two Clones: An in vitro Model of Intra-tumour heterogeneity


11 Sep 2017


Poster display session


Cancer Biology


Abdulazeez Salawu


Annals of Oncology (2017) 28 (suppl_5): v1-v21. 10.1093/annonc/mdx361


A. Salawu1, M. Fernando2, D. Hughes2, M. Reed3, P. Woll1, K. Sisley4

Author affiliations

  • 1 Academic Unit Of Clinical Oncology, Weston Park Hospital Cancer Research Centre, S10 2SJ - Sheffield/GB
  • 2 Histopathology, Sheffield Teaching Hospitals, S10 2JF - Sheffield/GB
  • 3 Brighton And Sussex Medical School, University of Sussex, BN1 9PX - Brighton/GB
  • 4 Oncology And Metabolism, University of Sheffield, S10 2RX - Sheffield/GB


Abstract 5223


Eradication of advanced disease remains elusive in the majority of cancers including soft tissue sarcomas (STS) despite advances in our understanding of the molecular mechanisms that drive them. Targeted treatment development to date has largely relied upon data derived from all cells within a tumour sample and/or tumour cell lines. These approaches however, do not account for inherent heterogeneity of cancer cells within a single tumour and is considered an important factor that leads to treatment failure. Understanding intra-tumour heterogeneity is therefore a priority for cancer research and appropriate tumour models with sufficient availability would greatly facilitate the identification of newer targets and factors that lead to treatment resistance. We therefore aimed to develop in vitro models of STS that reflect intra-tumour heterogeneity.


We obtained tissue from patients having surgery for STS in Sheffield Teaching Hospitals and established primary tissue cultures. Short Tandem Repeat (STR) confirmed the same origin of both clones in both cases. DNA copy number profiling and gene expression microarray analysis were used for molecular characterisation of self-immortalised primary cell lines.


One leiomyosarcoma (Shef-LMS 01) and one myxofibrosarcoma cell line (Shef-MFS 01) established two morphologically-distinct tumour cell types (culture variants) in separate long term cultures. Karyotyping and growth characteristics confirm that both variants in each case are tumour cells and they have remained in culture for over 100 passages. STR profiling confirms that in each case, both clones are derived from the same tumour. DNA copy number analysis with microarray-based comparative genomic hybridisation and gene expressson analysis shows many identical somatic copy number abnormalities (SCNA) between variants, but also numerous genomic and transcriptomic differences.


We believe that these genomic and transcriptomic differences provide clues to clonal evolution in these tumours and may explain the development of resistance to targeted treatment. These cell lines are therefore useful for the identification of novel targets and development of effective therapies for these tumours.

Clinical trial identification

Legal entity responsible for the study

Abdulazeez Salawu


Weston Park Cancer Charity and Sarcoma UK


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.